Structure of AZD3965
CAS No.: 1448671-31-5
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
AZD3965 is a selective monocarboxylate transporter 1 (MCT1) inhibitor with high affinity for MCT1, with an IC50 value of 3 nM. AZD3965 has antitumor effects and can be used in research on cancers related to lactate metabolism.
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Wegner, Scott A ; Kim, Hahn ; Avalos, José L ;
Abstract: Lactate transport plays a crucial role in the metabolism, microenvironment, and survival of cancer cells. However, current drugs targeting either MCT1 or MCT4, which traditionally mediate lactate import or efflux respectively, show limited efficacy beyond in vitro models. This limitation partly arises from the existence of both isoforms in certain tumors, however existing high-affinity MCT1/4 inhibitors are years away from human testing. Therefore, we conducted an optogenetic drug screen in Saccharomyces cerevisiae on a subset of the FDA-approved drug library to identify existing scaffolds that could be repurposed as monocarboxylate transporter (MCT) inhibitors. Our findings show that several existing drug classes inhibit MCT1 activity, including non-steroidal estrogens, non-steroidal anti-inflammatory drugs (NSAIDs), and natural products (in total representing approximately 1% of the total library, 78 out of 6400), with a moderate affinity (IC50 1.8–21 μM). Given the well-tolerated nature of NSAIDs, and their known anticancer properties associated with COX inhibition, we chose to further investigate their MCT1 inhibition profile. The majority of NSAIDs in our screen cluster into a single large structural grouping. Moreover, this group is predominantly comprised of FDA-approved NSAIDs, with seven exhibiting moderate MCT1 inhibition. Since these molecules form a distinct structural cluster with known NSAID MCT4 inhibitors, such as diclofenac, ketoprofen, and indomethacin, we hypothesize that these newly identified inhibitors may also inhibit both transporters. Consequently, NSAIDs as a class, and piroxicam specifically (IC50 4.4 μM), demonstrate MCT1 inhibition at theoretically relevant human dosages, suggesting immediate potential for standalone MCT inhibition or combined anticancer therapy.
Show More >
Purchased from AmBeed: 61-68-7 ; 22071-15-4 ; 1448671-31-5 ; 169590-42-5 ; 71125-38-7 ; 29679-58-1 ; 42924-53-8 ; 162011-90-7 ; 500-38-9
Show More >
CAS No. : | 1448671-31-5 |
Formula : | C21H24F3N5O5S |
M.W : | 515.51 |
SMILES Code : | O=C1N(C(C)C)C2=C(C(C(N3OC[C@@](C)(O)C3)=O)=C(CC4=C(C)NN=C4C(F)(F)F)S2)C(N1C)=O |
MDL No. : | MFCD28963899 |
InChI Key : | PRNXOFBDXNTIFG-FQEVSTJZSA-N |
Pubchem ID : | 10369242 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H335 |
Precautionary Statements: | P261-P305+P351+P338 |
In Vitro:
Cell Line
|
Concentration | Treated Time | Description | References |
K-562 | 1 nM to 10 µM | 72 hours | Evaluate the effect of AZD3965 on K-562 cells, showing that K-562 cells exhibit unique sensitivity to AZD3965 | PMC8671470 |
BV-173 | 1 nM to 10 µM | 72 hours | Evaluate the effect of AZD3965 on BV-173 cells, showing that BV-173 cells exhibit unique sensitivity to AZD3965 | PMC8671470 |
Raji human lymphoma cells | 2nM to 25nM | 24 hours | AZD3965 induced accumulation of Lactate I, which became more pronounced with increasing drug concentrations, reaching a maximum at 25nM. | PMC5669455 |
Raji human lymphoma cells | 25nM | 15 minutes to 72 hours | AZD3965 induced rapid build-up of Lactate I, showing a trend towards an increase as early as 15 minutes, becoming significant after 90 minutes, peaking at around 3h, then showing a gradual decrease from 6h up to 72h post-treatment. | PMC5669455 |
Hut78 human lymphoma cells | 5nM to 500nM | 24 hours | AZD3965 induced a 10-fold build-up in Lactate I in Hut78 cells at 5nM, which was sustained at higher drug concentrations. | PMC5669455 |
HT29 human colon carcinoma cells | 5nM to 500nM | 24 hours | AZD3965 induced a significant increase in Lactate I in HT29 cells at 500nM, reaching up to 4-fold relative to controls. | PMC5669455 |
αCD19-CAR T cells | 100 nM | 24-48 hours | MCT-1 inhibition induced metabolic rewiring in CAR T cells, increasing mitochondrial mass but not significantly affecting their effector function and phenotype | PMC10314680 |
Raji cells | 100 nM | 48 hours | MCT-1 inhibition significantly increased intracellular lactate accumulation in Raji cells and reduced their extracellular acidification rate | PMC10314680 |
Raji human lymphoma cells | 2nM, 25nM | 24 hours | AZD3965 induced accumulation of intracellular lactate, inhibited monocarboxylate influx and efflux, and increased TCA cycle-related metabolites and 13C-glucose mitochondrial metabolism. | PMC5669455 |
Hut78 human lymphoma cells | 5nM, 25nM, 500nM | 24 hours | AZD3965 induced accumulation of intracellular lactate, inhibited monocarboxylate influx and efflux, and increased TCA cycle-related metabolites and 13C-glucose mitochondrial metabolism. | PMC5669455 |
HT29 human colon carcinoma cells | 5nM, 25nM, 500nM | 24 hours | AZD3965 induced accumulation of intracellular lactate, inhibited monocarboxylate influx and efflux, and increased TCA cycle-related metabolites and 13C-glucose mitochondrial metabolism. | PMC5669455 |
TC-1 cancer cells | 1 × 10^−6 M | 24 hours | AZD3965 significantly decreased lactate secretion and inhibited the lowering of pH in the medium | PMC7674253 |
WERI-Rb1 | 100 nM | 48 hours | Inhibition of MCT1 led to a significant reduction in RB cell proliferation, increased intracellular lactate accumulation, increased ADP/ATP ratio, and reduced mitochondrial membrane potential. | PMC11088057 |
Y79 | 100 nM | 48 hours | Inhibition of MCT1 led to a significant reduction in RB cell proliferation, increased intracellular lactate accumulation, increased ADP/ATP ratio, and reduced mitochondrial membrane potential. | PMC11088057 |
SMS-SAN | 1 μM | 48 h | Measure lactate and GSH/GSSG ratio | PMC8020796 |
IMR5 | 1 μM | 16 h | Measure ECAR and OCR | PMC8020796 |
PBMC-derived macrophages | 20 μM | 3 hours | To evaluate the effect of exogenous lactic acid on macrophage polarization, results showed that lactic acid promotes M2 polarization under normoxia and M1 polarization under hypoxia. | PMC8741856 |
DLBCL cell lines | 100 nM | 72 hours | AZD3965 potently inhibited the proliferation of DLBCL cell lines | PMC5566036 |
BL cell lines | 100 nM | 72 hours | AZD3965 potently inhibited the proliferation of BL cell lines | PMC5566036 |
CA46 cells | 10 nM | 7 weeks | CA46 cells developed adaptive resistance to AZD3965, with increased dependency on oxidative phosphorylation | PMC5566036 |
HS578T cells | 250 nM | 24 hours | AZD3965 treatment induced a gene expression signature that strongly resembles that of SUM149PT cells with stable MCT1 knockdown, enhancing oxidative metabolism. | PMC4816454 |
SUM149PT cells | 250 nM | 24 hours | AZD3965 treatment reduced proliferation rates of SUM149PT cells and increased intracellular pyruvate levels. | PMC4816454 |
SUM159PT cells | 250 nM | 24 hours | AZD3965 treatment reduced proliferation rates of SUM159PT cells and increased intracellular pyruvate levels. | PMC4816454 |
In Vivo:
Species
|
Animal Model
|
Administration | Dosage | Frequency | Description | References |
mice | Raji xenograft tumor model | oral | 0.5, 1, 2, 4, 30 μM | Single injection | AZD3965 treatment improved tumor bioenergetics, as detected by in vivo 31P NMR spectroscopy, with increased β-NTP/Pi and β-NTP/total P ratios, indicating increased tumor lactate accumulation but no change in tumor acidification. | PMC5669455 |
NOD/SCID mice | B-cell leukemia xenograft model | intraperitoneal injection | 80 mg/kg | Every 8 hours, for a total of 3 doses | Combination of MCT-1 inhibition with CAR T cells significantly reduced tumor burden without affecting T-cell phenotype | PMC10314680 |
Mice | Raji xenograft model | Oral | 50 mg/kg | twice daily for 5 days | AZD3965 improved tumor bioenergetics, increasing the ratios of β-NTP/Pi and β-NTP/total P, indicating an improved bioenergetic state. | PMC5669455 |
Mice | TC-1 tumor model | Intravenous injection | 5 mg/kg | daily injections for 12 days | AZD-UPS NP significantly inhibited tumor growth and increased survival | PMC7674253 |
BALB/c nude mice | Retinoblastoma xenograft model | Intravitreal injection | 50 mg/kg | Twice daily for 5 days | AZD3965 effectively suppressed RB xenograft tumor growth, reduced tumor burden, and altered the expression pattern of pAMPK/pmTOR/pS6. | PMC11088057 |
mice | SMS-SAN MYCN-amplified NB xenograft model | oral | 2 mg/kg | Administered on day 7, 10, and 13 | Evaluate the effect of AZD3965 and phenformin combination on tumor growth | PMC8020796 |
Mice | Abortion-prone mouse model | Oral | 1 nM, 10 nM, 100 nM | Single injection, duration of 28 days | To evaluate the therapeutic effect of AZD3965 on the abortion-prone mouse model, results showed that AZD3965 significantly reduced the embryo resorption rate. | PMC8741856 |
Mice | CA46 Burkitt lymphoma model | Oral | 100 mg/kg/qd/po AZD3965 and 100 mg/kg/qd/po phenformin | once daily for 2 weeks | AZD3965 significantly inhibited CA46 Burkitt lymphoma growth by 99% | PMC5566036 |
NOD scid gamma (NSG) mice | Mammary fat pad xenograft tumor model | Oral | 100 mg/kg | Twice daily for 24 days | AZD3965 treatment significantly inhibited the growth of mammary fat pad xenograft tumors but did not reduce tumor FDG uptake. | PMC4816454 |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
1.94mL 0.39mL 0.19mL |
9.70mL 1.94mL 0.97mL |
19.40mL 3.88mL 1.94mL |
Tags: AZD3965 | AZD 3965 | AZD-3965 | MCT1 inhibitor | lactate transport | tumor metabolism | monocarboxylate transporter | aerobic glycolysis | Warburg effect | MCT2 | 1448671-31-5
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :
Total Compounds: mg
The concentration of the dissolution solution you need to prepare is mg/mL